Top

Published in:

Open Access 01-07-2014 | Research Article

PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer

Authors: Anna Pryczynicz, Katarzyna Guzińska-Ustymowicz, Katarzyna Niewiarowska, Dariusz Cepowicz, Andrzej Kemona

Published in: Tumor Biology | Issue 7/2014

Abstract

E-cadherin, a transmembrane adhesion molecule, and phosphatase of regenerating liver 3 (PRL-3) protein, a member of the family of tyrosine phosphatases, seem to be responsible for cancer cell migration. Therefore, the study objective was to determine a correlation between PRL-3 and E-cadherin, to assess their expression in neoplastic tissue and normal mucosa of the stomach, to analyze their effect on cancer advancement, and to evaluate their potential as prognostic markers in gastric cancer. The expressions of PRL-3 and E-cadherin were assessed immunohistochemically in 71 patients with gastric cancer. Positive expression of PRL-3 was observed in 42.2 % of gastric cancer cases, whereas E-cadherin expression was abnormal in 38 % of cases. The study revealed that the positive PRL-3 expression and abnormal E-cadherin expression were associated with mucinous gastric carcinoma and lymph node involvement. The former was also related to the infiltrating type of tumor and abnormal E-cadherin expression. The expression of PRL-3, but not of E-cadherin, was associated with shorter survival of patients. PRL-3 and E-cadherin exhibit interactions in gastric cancer and are involved in the formation of lymph node metastases. The PRL-3 protein can be an independent predictive factor of overall survival in gastric cancer patients.

Zeng Q, Hong W, Tan YH. Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1. Biochem Biophys Res Commun. 1998;244:421–7.CrossRefPubMed

Guzińska-Ustymowicz K, Pryczynicz A. PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis. Anticancer Agents Med Chem. 2011;11:99–108.CrossRefPubMed

Fiordalisi JJ, Keller PJ, Cox AD. PRL tyrosine phosphatases regulate rho family GTPases to promote invasion and motility. Cancer Res. 2006;66:3153–61.CrossRefPubMed

Forte E, Orsatti L, Talamo F, Barbato G, De Francesco R, Tomei L. Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. Biochim Biophys Acta. 2008;1783:334–44.CrossRefPubMed

Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10:182–6.CrossRefPubMed

Mizuuchi E, Semba S, Kodama Y, Yokozaki H. Down-modulation of keratin 8 phosphorylation levels by PRL-3 contributes to colorectal carcinoma progression. Int J Cancer. 2009;124:1802–10.CrossRefPubMed

Zheng P, Liu YX, Chen L, Liu XH, Xiao ZQ, Zhao L, et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res. 2010;9:4897–905.CrossRefPubMed

Peng L, Jin G, Wang L, Guo J, Meng L, Shou C. Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3. Biochem Biophys Res Commun. 2006;342:179–83.CrossRefPubMed

Peng L, Xing X, Li W, Qu L, Meng L, Lian S, et al. PRL-3 promotes the motility, invasion, and metastasis of LoVo colon cancer cells through PRL-3-integrin beta1-ERK1/2 and-MMP2 signaling. Mol Cancer. 2009;8:110.PubMedCentralCrossRefPubMed

10.

Wang Y, Li ZF, He J, Li YL, Zhu GB, Zhang LH, et al. Expression of the human phosphatases of regenerating liver (PRLs) in colonic adenocarcinoma and its correlation with lymph node metastasis. Int J Color Dis. 2007;22:1179–84.CrossRef

11.

Van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci. 2008;65:3756–88.CrossRefPubMed

12.

Carneiro P et al. E-cadherin dysfunction in gastric cancer—cellular consequences, clinical application and open questions. FEBS Lett. 2012;586:2981–9.CrossRefPubMed

13.

Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994;1198:11–26.PubMed

14.

Birchmeier W, Weidner KM, Hulsken J. Molecular mechanism leading to cell junction (cadherin) deficiency in invasive carcinomas. Semin Cancer Biol. 1993;4:231–9.PubMed

15.

Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed

16.

Kubo G, Kubo T, Kubo K. Differences in the mode of extension of gastric cancer classified by histological type: new histological classification of gastric carcinoma. Gut. 1992;33:606–12.CrossRef

17.

Borrmann R. Geshwulste des Magens und Duodenums. In: Henker F, Lubarsh D, editors. Handbuchder Spezieller Pathologischen: Anatomie und Histolgie, vol. IV. Berlin: Springer; 1926. p. 865.

18.

Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15:740–6.CrossRefPubMed

19.

Wang H, Quah SY, Dong JM, et al. PRL-3 down-regulates PTEN expression and signals trough PI3K to promote epithelial-mesenchymal transition. Cancer Res. 2007;67:2922–6.CrossRefPubMed

20.

Liu Y, Zhou J, Chen J, Gao W, Le Y, Ding Y, et al. PRL-3 promotes epithelial mesenchymal transition by regulating cadherin directly. Cancer Biol Ther. 2009;8:1352–9.CrossRefPubMed

21.

Lazăr D, Tăban S, Ardeleanu C, Dema A, Sporea I, Cornianu M, et al. The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients’ survival. Rom J Morphol Embryol. 2008;49:459–67.PubMed

22.

Bilici A, Ustaalioglu BB, Yavuzer D, Seker M, Mayadagli A, Gumus M. Prognostic significance of high phosphatase of regenerating liver-3 expression in patients with gastric cancer who underwent curative gastrectomy. Dig Dis Sci. 2012;57:1568–75.CrossRefPubMed

23.

Tang B, Peng ZH, Yu PW, Yu G, Qian F. Expression and significance of Cx43 and E-cadherin in gastric cancer and metastatic lymph nodes. Med Oncol. 2011;28:502–8.CrossRefPubMed

24.

Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M. Phosphatase of regenerating liver-3 as a prognostic biomarker in histologically node-negative gastric cancer. Oncol Rep. 2009;21:1467–75.PubMed

25.

Li Y, Chen CQ, He YL, Cai SR, Yang DJ, He WL, et al. Abnormal expression of E-cadherin in tumor cells is associated with poor prognosis of gastric carcinoma. J Surg Oncol. 2012;106:304–10.CrossRefPubMed

Title: PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer
Authors: Anna Pryczynicz
Katarzyna Guzińska-Ustymowicz
Katarzyna Niewiarowska
Dariusz Cepowicz
Andrzej Kemona
Publication date: 01-07-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-1855-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2014

EphB4 regulates the growth and migration of pancreatic cancer cells

Expression of basic fibroblast growth factor, CD31, and α-smooth muscle actin and esophageal cancer recurrence after definitive chemoradiation

Interleukin 15 receptor alpha rs2228059 A > C polymorphism decreased risk of gastric cardiac adenocarcinoma in a Chinese population

Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?

MicroRNA-195 regulates steroid receptor coactivator-3 protein expression in hepatocellular carcinoma cells

Correlation between overexpression of EpCAM in prostate tissues and genesis of androgen-dependent prostate cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer